Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer [ID1429]
Discontinued
Reference number: GID-TA10512
The Department for Health and Social Care has asked NICE to conduct an appraisal of Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer.
Please note that following on from information received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early-August 2021 when we will write to you about how you can get involved.